THE Federal Court has issued final orders relating to claims that AFT Pharmaceuticals' Maxigesic is more efficacious than paracetamol or ibuprofen alone.
The orders reflect a judgement made by the Court last month (PD 05 Aug), which ruled AFT had engaged in misleading or deceptive conduct in contravention of Australian Consumer Law.
RB Health, the sponsor of ibuprofen brand, Nurofen, and ibuprofen and paracetamol combination medication, Nuromol, welcomed the decision.
"With this matter now resolved RB Health looks forward to continuing to work on our objective to make access to the highest quality health and wellness solutions for all Australians a right not a privilege," a spokesperson said.
The Court awarded costs to RB.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 20
